we read with great interest the article published by hosseini et al. 1 in october issue of middle east journal of digestive diseases. briefly, in this article, authors concluded that furazolidone based therapeutic regimens (in moderate and even high-dose) were not preferable for first-line treatment against h. pylori infection among the northern population in iran. 1 altogether, some points we ...